Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

Articles

A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed. 

Standard Criteria for Loss of Ambulation Needed in DMD

The findings suggest there are ongoing disparities between Black and White patients with hepatocellular carcinoma (HCC) in terms of both outcomes and health care resource utilization.

Real-World Data Show Racial Disparities in HCC Outcomes, Resource Utilization  

A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.


Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome

Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year. 

An Overview of Health Care and Pharmaceutical Trends, 2023-2024

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

View

Goals and Objectives

Introduction

Applying Lipid Clinical Trials to the Practical Management of High-Risk Patients

Integrating Risk Factor Management into the Care of the Cardiac Patient

Risk-Factor Management in Women and Other Special Patients

Clinical Implications of Recent Cholesterol Lowering Trials for the Secondary Prevention of Coronary Heart Disease

Risk Factor Management:  Exploring the Boundaries

CME Quiz

Bibliography

Converting Clinical Lipid Trials into the Practical Management of High-Risk Patients: New NECP Thoughts on Treating CHD Patients

Review of the NIH Post-CABG Study and Future Advances in HMG-CoA Therapy

Accuracy of Lipid Profiles in the Hospital Setting: Impact on the Initiation of Cholesterol-Lowering Therapy

The Undertreatment Problem: Identifying Barriers to Treatment

Practical Disease Management as a Solution to the Undertreatment Problem

Impact of Risk Factor Modification on the CHD Process

Integrating Risk Factor Management of Coronary Heart Disease into Managed Care

SUPPLEMENT CONTENT

Supplements

Publications

Safety and Tolerability of Lipid-Lowering Drugs After Heart Transplantation: The Heart Transplant Lipid Registry